A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (

A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP-3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Obert

Codi protocol: AZP-3601-CLI-002
Codi EudraCT: _
Grup de recerca: Diabetis i Metabolisme
Servei: Endocrinologia
Investigador/a principal: Fidilio Meli, Enzamaría
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III
Estat: Reclutant voluntaris